@Article{,
AUTHOR = {Mostafa M. Elhilali, J. Curtis Nickel},
TITLE = {Benign prostatic hyperplasia: from A – Z},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {2},
PAGES = {1799--1802},
URL = {http://www.techscience.com/CJU/v10n2/62688},
ISSN = {1488-5581},
ABSTRACT = {The management of lower urinary tract symptoms
(LUTS) secondary to benign prostatic hyperplasia over
the last decade underwent many changes.
The introduction of many medical options including
alpha blockers and 5 alpha reductase inhibitors provided
alternatives to what used to be surgery or “watchful
waiting”.<br/>
Alpha blockers evolved over the years from non specific
alpha blockers to alpha 1 selective and then to alpha 1a
selective with a wider acceptance due to lack of need to
titrate and a better safety profile.<br/>
5 alpha reductase inhibitor (finasteride) passed through
a lot of changes from being the first medication directed
at treating the disease process to less acceptance because
of time to response and early data supporting no added
benefit when combined to alpha blockers for a short period.
Longer studies now demonstrate a benefit to combination
causing a reduction of progression parameters and an
advantage over 4 years in reducing endpoints, namely
acute urinary retention and surgery. Surgical options
have also undergone many changes over the last decade
with introduction of minimally invasive options as well
as the introduction of new energy sources to reduce
complications and allow for management of larger glands
such as Holmium laser enucleation of the prostate or the
use of bipolar loops.<br/>
The journey has been long and exciting and we are sure
Ernie Ramsey enjoyed being in the forefront of the
evolution.},
DOI = {}
}